Pure Global AI
NCT06212388Not yet recruiting

Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma

Efficacy and Safety of Allogeneic γδ T Cells (γδ T Cells) Combined With Interferon-alpha1b (IFN-α1b) or PD-1 Monoclonal Antibody in Neoadjuvant Treatment of Stage III-IV Resectable Melanoma
Xijing HospitalPhase 1ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Melanoma
Drug/Device/Intervention
Ex-vivo expanded allogeneic γδ T cells
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Xijing Hospital
Timeline & enrollment
Phase
Phase 1
Start date
Jan 24, 2024
End date
Oct 30, 2028
Enrollment
10 participants
Primary outcome

Rate of Pathological Complete Response (pCR),Rate of Major Pathological Response (mPR),Rate of Partial Pathological Response (pPR),Overall Response Rate(ORR)

Summary

The purpose of this study is to evaluate the efficacy and safety of allogeneic γδ T cells
 combined with recombinant human interferon-α1b (IFN-α1b) or PD-1 monoclonal antibody in
 neoadjuvant treatment of patients with Stage III-IV resectable melanoma.

ICD-10 classifications
Malignant melanoma of skinMelanoma in situ, unspecifiedMelanoma in situMelanoma and other malignant neoplasms of skinMalignant neoplasm: Malignant melanoma of skin, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06212388
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06212388 through Pure Global AI's free database. This Phase 1 trial is sponsored by Xijing Hospital and is currently Not yet recruiting. The study focuses on Melanoma. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.